e-learning
resources
Munich 2014
Tuesday, 09.09.2014
Allergy and asthma: novel findings based on human cell biology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficacy and safety of 10 day treatment with the CRTh2 antagonist QAV680 evaluated in patients with allergic rhinitis in an environmental exposure chamber
V. J. Erpenbeck, A. M. Salapatek, P. Patel, J. Sanni, G. Dubois, P. Zhou, S. Perry, M. Larbig (Basel, Switzerland; Toronto, Canada; Horsham, West Sussex, United Kingdom)
Source:
International Congress 2014 – Allergy and asthma: novel findings based on human cell biology
Session:
Allergy and asthma: novel findings based on human cell biology
Session type:
Thematic Poster Session
Number:
4075
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. J. Erpenbeck, A. M. Salapatek, P. Patel, J. Sanni, G. Dubois, P. Zhou, S. Perry, M. Larbig (Basel, Switzerland; Toronto, Canada; Horsham, West Sussex, United Kingdom). Efficacy and safety of 10 day treatment with the CRTh2 antagonist QAV680 evaluated in patients with allergic rhinitis in an environmental exposure chamber. Eur Respir J 2014; 44: Suppl. 58, 4075
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Lung function in epidemiological studies from infancy to childhood with focus on urban environment
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
QAV680, cetirizine and their combination reduce nasal symptoms in patients with intermittent allergic rhinitis in an environmental exposure chamber
Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology
Year: 2014
Comparative efficacy of different groups of drugs for the treatment of bronchial asthma in combination with allergic rhinitis
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
Subcutaneous allergen specific immunotherapy and immunological response in patients with bronchial asthma and allergic rhinitis in India
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
Combined therapy of asthma and allergic rhinitis
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Ultra-rush sublingual immunotherapy: Safety of use for patients with various allergic manifestations
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015
Therapeutic effectpredictors during sublingual immunotherapy for Japanese seasonal allergic rhinitis
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
Effects of airborne pollen levels on drug consumption for seasonal allergic rhinoconjunctivitis: A ten-year French study
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
Intranasal GSK2245035 induces prolonged reductions in nasal responsiveness to allergen
Source: International Congress 2015 – The immunology of allergic airway disease
Year: 2015
Distribution of mast cells and their interactions with nerve in allergic rhinitis
Source: International Congress 2015 – Asthma and lung immunology
Year: 2015
Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy
Source: International Congress 2016 – Clinical and molecular studies in asthma
Year: 2016
Allergic rhinitis does it have an impact on controller asthma therapy choice
Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management
Year: 2014
LATE-BREAKING ABSTRACT: Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting the allergen-induced early asthmatic response
Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Year: 2014
Predictors factors for asthma in patients with rhinitis
Source: International Congress 2014 – Clinical allergy
Year: 2014
Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Clinical effectiveness of anti-IgE therapy in allergic severe asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Unexpected severe systemic allergic reaction after hymenoptera sting in well controlled asthma during treatment with omalizumab
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
Autoimmune disorders in allergen immunotherapy, allergic rhinitis, and non-allergic patients
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
Should patients with mild asthma be excluded from allergic rhinitis drug trials?
Source: International Congress 2015 – Immune mechanisms in the human lung
Year: 2015
Clinical characteristics of seasonal rhinitis and co-existence with asthma
Source: International Congress 2016 – Clinical studies in asthma and immunology
Year: 2016
25(OH) vitamin D levels in pediatric asthma and allergic rhinitis
Source: International Congress 2014 – More paediatric asthma
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept